Irbesartán Davur

Irbesartan, the active ingredient in Irbesartán Davur, is an angiotensin II receptor blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension and for slowing progression of diabetic nephropathy in adult patients.

GNH USA supplies Irbesartán Davur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU marketing authorisation standards and is manufactured under GMP conditions, ensuring consistent potency and purity for global distribution through reliable logistics.

Irbesartan is an angiotensin II receptor blocker used to treat conditions related to elevated blood pressure and renal impairment.

- Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Diabetic nephropathy: slows the decline of renal function in patients with type 2 diabetes. - Proteinuria: decreases urinary protein excretion in chronic kidney disease.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pressure in the head region. - Fatigue: general feeling of tiredness or lack of energy. - Hyperkalemia: elevated potassium levels detectable in blood tests.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Acute renal failure: sudden loss of kidney function requiring medical attention. - Hepatic enzyme elevation: increased liver transaminases indicating possible liver stress.

Before initiating therapy, clinicians should consider the following precautions: - Monitor blood pressure: ensure adequate control and avoid hypotension. - Check serum potassium: periodic testing to detect hyperkalemia. - Assess renal function: baseline and periodic creatinine measurements are recommended. - Avoid in severe hepatic impairment: limited data suggest caution. - Use caution during pregnancy: safety category is unknown, so benefits must outweigh risks. - Store at below 25°C: keep in the original container, protect from moisture.

Irbesartan may interact with several medicines; awareness of the following is important.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: combined use can increase renal risk. - Concurrent ACE inhibitor or another ARB: may cause excessive potassium rise and renal dysfunction. - Potassium‑sparing diuretics: increase the chance of hyperkalemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive effect. - Strong CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma levels.